Needham Sticks to Its Buy Rating for Intercept Pharma (ICPT)

By Carrie Williams

Needham analyst Alan Carr maintained a Buy rating on Intercept Pharma (ICPTResearch Report) today and set a price target of $150.00. The company’s shares closed last Monday at $75.23.

According to TipRanks.com, Carr is a 1-star analyst with an average return of -0.2% and a 42.4% success rate. Carr covers the Healthcare sector, focusing on stocks such as Biohaven Pharmaceutical Holding Co, Lexicon Pharmaceuticals, and ACADIA Pharmaceuticals.

Intercept Pharma has an analyst consensus of Strong Buy, with a price target consensus of $148.27, which is a 99.7% upside from current levels. In a report issued on October 28, Wedbush also reiterated a Buy rating on the stock with a $243.00 price target.

See today’s analyst top recommended stocks >>

Based on Intercept Pharma’s latest earnings release for the quarter ending June 30, the company reported a quarterly GAAP net loss of $71.42 million. In comparison, last year the company had a GAAP net loss of $64.45 million.

Based on the recent corporate insider activity of 100 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of ICPT in relation to earlier this year.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Intercept Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of novel therapeutics in treating chronic liver diseases. Its product pipeline is OCALIVA which is used for the treatment of primary biliary cholangitis, nonalcoholic steatohepatitis, primary sclerosing cholangitis, and biliary atresia. The company was founded by Mark E. Pruzanski and Roberto Pellicciari on September 4, 2002 and is headquartered in New York, NY.